NEXT Oncology Moves Cancer Research Forward

NEXT Oncology, a Phase 1 Clinical Trial organization with six locations around the world, played a significant role in moving cancer research forward at the recent American Society of Clinical Oncology (ASCO) meeting in Chicago.

Clinical investigators from NEXT locations around the world presented 25 abstracts, posters and presentations on the status of ongoing Phase 1 clinical trials at NEXT Oncology, including:

  • Dr. Anthony Tolcher, CEO and Founder of NEXT Oncology based in our San Antonio office with four abstracts;
  • Dr. Ildefonso Ismael Rodriguez, also with our San Antonio office –  three abstracts;
  • Dr. Shiraj Sen with our Dallas office –  two abstracts;
  • Dr. Andre Vandross with our Austin office – six abstracts;
  • Dr. Valentina Boni in our Madrid office – eight abstracts;
  • And Dr. Jesus Antras Fuentes, also in Madrid –  two abstracts.

“Each and every person on the NEXT Oncology team is dedicated to moving cancer research forward to solve cancer,” Dr. Anthony Tolcher, NEXT Oncology’s CEO and Founder, stated. “The important findings made at ASCO demonstrate our dedication to supporting the development of new therapies and approaches that will benefit patients everywhere.” 

About NEXT Oncology

NEXT Oncology is dedicated to the development of new anticancer agents for patients whose current cancer therapy is no longer working to benefit them and are looking for their next option. NEXT Oncology is partnered with  Texas Oncology, the largest private oncology practice in the United States with more than 400 referring medical oncologists. Texas Oncology is a practice within The US Oncology Network, a network of independent, community-based oncologists in the U.S. This formidable size and reach provide NEXT Oncology unprecedented opportunities to transform what has come to be expected from clinical trials of new agents.